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A case report of primary breast angiosarcoma with fatal 
pulmonary hemorrhage due to thrombocytopenia
Yong-Seok Kim, Young-Joong Kim, Kwang-Il Yim
1, Woo-Chan Park
Departments of Surgery and
 1Hospital Pathology, The Catholic University of Korea School of Medicine, Seoul, Korea
Primary angiosarcomas of the breast are rare malignancy that account for fewer than 0.04% of all malignant breast tumors. 
The prognosis is poor. Surgery is the first line of treatment for angiosarcoma. Adjuvant chemotherapy and radiotherapy have 
been tried, but their efficacy remains controversial. Here we present the case of a 47-year-old woman with a palpable left 
breast mass that was diagnosed as a primary angiosarcoma. The patient underwent modified radical mastectomy with ad-
juvant chemotherapy and radiotherapy. Postoperatively, eighteen months later, the angiosarcoma recurred. The patient re-
turned complaining of dyspnea and hemoptysis and was found to have a large pleural effusion. She developed a gradual on-
set of thrombocytopenia that persisted despite platelet transfusions. Finally, the patient died of respiratory failure secondary 
to pulmonary hemorrhage.
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INTRODUCTION
Angiosarcoma is a malignant neoplasm of endothelial 
cells that begins in the lining of the blood vessel wall. 
Although angiosarcoma of the breast is a rare entity, the 
breast is a favorable site for it [1]. Breast angiosarcomas 
may be categorized as primary or secondary angiosar-
coma.  
Primary angiosarcoma arises within the breast paren-
chyma, the overlying skin, and subcutaneous tissue. In 
contrast, secondary angiosarcoma of the breast is com-
monly associated with radiation therapy in patients who 
have undergone breast-conserving surgery for another 
type of primary neoplasm of the breast. These secondary 
angiosarcomas occur several years after the initial treat-
ment, are often associated with lymphedema, and involve 
the skin. Primary angiosarcomas account for fewer than 
0.04% of all malignant breast neoplasms, and tend to occur 
in younger patients with no prior history of malignancy 
[1,2].
The prognosis is poor for patients with primary angio-
sarcomas as compared with invasive ductal carcinomas. 
Angiosarcomas are highly aggressive vascular and soft 
tissue malignancies. Angiogenesis, believed to be strongly 
influenced by vascular endothelial growth factor (VEGF), 
is crucial in the pathogenesis of these tumors. The histo-Yong-Seok Kim, et al.
252 thesurgery.or.kr
Fig. 1. Sonography and magnetic 
resonance imaging revealed irre-
gular spiculated mass in left breast.
logic grade of primary angiosarcoma of the breast plays an 
important role in the prediction of outcomes [3,4]. Because 
high-grade primary breast sarcomas behave like ex-
tremity sarcomas, some authors have advocated using the 
same treatment protocol: surgical resection followed by 
adjuvant chemotherapy and radiotherapy [5]. Because of 
its rarity, the clinical course of primary breast angiosarco-
ma remains unclear, although metastases involving lung, 
liver, and other organs have been reported. 
Here we present the clinical course of a 47-year-old fe-
male with primary angiosarcoma of the breast which 
showed recurrence to the chest wall and fatal lung compli-
cation with the review of literature. 
CASE REPORT
A 47-year-old female presented with a lump in the left 
breast in September 2009. She had no history of pain or 
nipple discharge. There was no significant past medical 
history.
Sonography demonstrated an irregular, spiculated, 1.7 
cm hypoechoic nodule in the upper inner quadrant of the 
left breast, accompanied by skin thickening and edema-
tous change (Fig. 1). A core needle biopsy identified an 
atypical angiomatous lesion, and the diagnosis of angio-
sarcoma was confirmed by positive results for factor 
VIII-related antigen and CD34. Because the patient had no 
history of previous radiation therapy or surgery, we classi-
fied the tumor as a primary angiosarcoma.
On dynamic magnetic resonance imaging (MRI), the 
mass exhibited early rapid enhancement with plateau. 
The MRI also detected lymph node enlargement in the left 
axilla (Fig. 1).
A positron emission tomography (PET)/computed to-
mography (CT) scan confirmed an area increased fluo-
rodeoxyglucose uptake in the upper inner quadrant of the 
affected breast with faint uptake by the lymph nodes in the 
left axilla, but no other metastatic lesions were found.
The patient underwent a modified radical mastectomy 
in October 2009. Grossly, there is a 3.0 × 1.5 × 1.4 cm sized 
ill defined dark brown hemorrhagic spongy mass in the 
upper outer quadrant of breast. Microscopically, the mass 
composed of epithelioid areas, spindle areas and necrosis. 
The epithelioid areas are made up of large rounded cells of 
high nuclear grade which are arranged in sheets or rudi-
mentary vascular channels (Fig. 2A). The spindle areas 
show vasoformative growth with complex anastomosing 
channels (Fig. 2B). These neoplastic channels are irregular 
in shape, freely intercommunicating with one another in a 
sinusoidal fashion. The mass shows high mitotic count 
(14/10 HPF), high nuclear grade and necrosis, the diag-
nosis is angiosarcoma, grade 3 in World Health Organiza-
tion classification. There is no lymph node metastasis. On 
immunohistochemical staining, the tumor was negative 
for estrogen receptor, progesterone receptor and HER2. 
The tumor was positive for VEGFR-2 and CD-34 (Fig. 2C).
The patient was treated with adjuvant chemotherapy of Primary breast angiosarcoma with fatal pulmonary hemorrhage
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Fig. 2. (A) Epithelioid areas of angiosarcoma (H&E, ×400). (B) Spindle vasoformative growth areas of angiosarcoma (H&E, ×400). (C) CD34 
immunohistochemical staining results shows diffuse strong positive in tumor cells (×400).
Fig. 3. (A) Chest X-ray showed large 
amount of pleural effusion in left 
side and mediastinal shifting to 
right side. (B) Chest X-ray showed 
secreased amount of pleural effu-
sion in left side.
Fig. 4. (A) Chest computed tomo-
graphy showed pulmonary hemor-
rhage in left side and pleural 
effusion in right side. (B) Recurrent 
angiosarcoma was observed in left 
chest wall.
doxorubicin (60 mg/m
2) and ifosfamide (5,000 mg/m
2) ev-
ery 3 weeks for six cycles from November 2009 until 
February 2010.
Following this, the patient underwent radiation ther-
apy on the left chest wall with 50 Gy for 5.5 weeks. CT, and 
bone scan were normal. A biopsy was done in the left 
axilla. Histological diagnosis was lymphangioendothelio-
ma, which was benign. We decided on follow-up 6 months 
later due to the possibility of local recurrence.
In January 2011, the patient returned complaining of Yong-Seok Kim, et al.
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dyspnea that had started 1 week prior. A chest X-ray 
showed a large pleural effusion in the left side (Fig. 3A). 
Chest CT verified a massive pleural effusion with com-
plete atelectasis in the left lung. A chest tube was placed to 
drain the effusion and 3,600 mL of dark, sanguineous fluid 
was emptied. Pleural biopsy and fluid cytology were 
done. On histological examination, there was no definite 
malignant lesion but a marked proliferation of vascular 
endothelial cells, which was thought to be a reactive 
change. 
During this admission, the patient’s initial platelet 
count was normal, but she developed a gradual onset of 
thrombocytopenia that persisted until discharge (2 months 
later) despite platelet transfusions. Effusion decreased 
gradually and chest tube was removed, but the patient’s 
condition was not yet improved (Fig. 3B). She left the hos-
pital arbitrarily.
The patient presented again with dyspnea and hemopt-
ysis in April 2011. Chest X-ray and CT showed pulmonary 
hemorrhage in the left side and pleural effusion in the 
right side (Fig. 4A). A chest tube was placed to drain the ef-
fusion and sanguineous output was noted. The patient 
was anemic and again remained thrombocytopenic in 
spite of transfusion. The skin lesion had been observed in 
left chest wall (Fig. 4B). Biopsy was done and histological 
examination established the diagnosis of recurrent grade 3 
angiosarcoma. Persistent hemoptysis and pleural effusion 
were not improved.
After diagnosis of recurrent angiosarcoma, we tried 
combination treatment with bevacizumab and paclitaxel 
with informed consent. After the first treatment, the pa-
tient’s respiratory symptoms improved, but after five 
days, her respiratory status again deteriorated. The pa-
tient died of respiratory failure secondary to pulmonary 
hemorrhage. 
DISCUSSION
Angiosarcomas are rare malignant tumors that arise 
from vascular endothelial cells. In general, they develop in 
the soft tissue and skin. Patients with primary angiosarco-
ma of the breast present with a palpable mass. There are no 
typical radiologic characteristics in mammography or 
sonography. MRI will reveal a heterogeneous mass with 
low signal intensity on T1-weighted images and high sig-
nal intensity on T2-weighted images due to the vascular 
endothelial origin of the tumor [6].
Immunohistochemical stains for factor VIII-related an-
tigen and CD34 are helpful to confirm the diagnosis of 
angiosarcoma. In this case, on initial core needle biopsy, 
immunohistochemical examinations were positive for the 
expression of factor VIII-related antigen and confirmed 
the diagnosis of angiosarcoma.
Primary angiosarcomas of the breast are classified into 
three grades [4]. Grade 1 (low grade) tumors consist of vas-
cular channels invading the breast fat and parenchyma 
with little or no endothelial proliferation. Grade 2 (inter-
mediate grade) tumors contain solid neoplastic vascular 
growth and papillary endothelial components. Grade 3 
(high-grade) tumors present as sarcomatous growths with 
necrosis and hemorrhage. In the case presented here, 
breast and skin biopsies were consistent with grade 3 pri-
mary angiosarcoma. 
The clinical course for this patient was very difficult due 
to the recurrence of tumor and complicated by an intract-
able thrombocytopenia. There are two hypotheses that 
may explain this thrombocytopenia. The first is that it was 
due to antiplatelet antibody. The second is that it may have 
resulted from antitumoral consumption of platelets. This 
platelet consumption may have been due to defective syn-
thesis of prostaglandin I2 by neovascular endothelium or 
to the release of a platelet aggregating substance by tumor 
cells [7]. Endothelial cells express several kinds of cell ad-
hesion molecules, including ICAM-1, VCAM-1, and 
PECAM-1 [8], but in this case, we were not able to evaluate 
for these molecules. Such an evaluation may have been 
useful to confirm that the patient’s thrombocytopenia was 
due to the angiosarcoma. 
Uncontrolled Thrombocytopenia in this case is similar 
with the consumptive coagulopathy seen in Kasabach- 
Meritt syndrome, which is characterized by platelet se-
questration and consumption of clotting factors within the 
vascular bed of giant angiomatous naevi [9]. The wide-
spread skin lesion, which was diagnosed as angiosarcoma 
had been observed in the left chest wall. So, we deemed Primary breast angiosarcoma with fatal pulmonary hemorrhage
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that the uncontrolled thrombocytopenia was caused by 
persistent platelet consumption in the large skin lesion. 
In high-grade angiosarcoma, the current treatment mo-
dalities are surgery followed by adjuvant chemotherapy 
and radiotherapy. Doxorubicin-based chemotherapy has 
been the mainstay of treatment for high-grade soft tissue 
sarcomas, and while adjuvant chemotherapy is recom-
mended for grade 3 tumors, little benefit has been re-
ported for grade 1 or grade 2 tumors [4].
Bevacizumab is a humanized monoclonal immuno-
globulin G1 antibody that targets VEGF, prevents binding 
of VEGF to receptors on vascular endothelial cells, and 
blocks tumor angiogenesis. It has demonstrated efficacy 
as a first line treatment of metastatic breast cancer, espe-
cially in combination with paclitaxel and docetaxel. Phase 
II trials evaluating the efficacy bevacizumab with paclitax-
el for angiosarcoma are currently under way [10]. On the 
basis of this trial, we tried bevacizumab treatment after in-
formed consent. 
The prognosis is poor in patients with primary breast 
angiosarcoma compared with other types of breast carci-
noma and is dependent on tumor grade. Disease-free sur-
vival 5 years after initial treatment is 76% with grade 1 tu-
mors and falls to 15% with grade 3 tumors. Disease re-
currence is more than 15 years with grade 1 tumors, but in 
patients with grade 3 tumors, the time to recurrence aver-
ages 15 months [4]. In this case, the patient had a grade 3 
tumor and the time to disease recurrence was about 18 
months. 
Metastases occur most frequently to the lung, bone, liv-
er, and chest wall [1]. Although not confirmed by biopsy, 
this patient had evidence of metastasis to the lung. She de-
veloped dyspnea, hemoptysis, and episodes of pleural 
hemorrhage beginning about 18 months after initial treat-
ment and persisting until death. The hemoptysis is consid-
ered to have been caused by alveolar hemorrhage secon-
dary to the suspected pulmonary metastasis, rather than 
spontaneous bleeding secondary to the thrombocyto-
penia. We suggest the patient died due to uncontrolled 
bleeding stemming from the alveolar hemorrhage.  
Because primary angiosarcoma of the breast is so ag-
gressive and rare, there is currently no consensus data for 
standard treatment or clinical course. We have detailed 
our experience with a primary breast angiosarcoma that 
failed to respond to multimodality treatment of surgical 
resection and adjuvant chemotherapy and radiotherapy. 
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